We examined how methods used for identifying dementia in administrative claims affected dementia incidence across racial/ethnic populations using a 100% sample of Medicare beneficiaries (n = 23,793,452). We found levels differed by method from 3.1% annual incidence to 3.6% in 2014. Dementia incidence declined from 2007 to 2014, but choice of method differentially impacted levels and trends by race/ethnicity. Methods using codes for dementia diagnosis and drugs to treat symptoms identified proportionally more Hispanics and Asians with dementia than other race/ethnicities, while codes for dementia diagnosis, drugs, and symptoms identified proportionally more whites and American Indians/Alaska Natives with dementia than other race/ethnicities.
BlackCM, FillitH, XieL, HuX, KariburyoMF, AmbegaonkarBM, BaserO, YuceH, KhandkerRK (2018) Economic burden, mortality, and institutionalization in patients newly diagnosed with Alzheimer’s disease. J Alzheimers Dis61, 185–193.
2.
GildenMD, KubisiakMJ, SarsourAK, HunterAC (2015) Diagnostic pathways to Alzheimer disease: Costs incurred in a medicare population. Alzheimer Dis Assoc Disord29, 330–337.
3.
SalberPR, SeleckyCE, SoenksenD, WilsonT (2018) Impact of dementia on costs of modifiable comorbid conditions. Am J Manag Care24, e344–e351.
4.
GoodmanRA, LochnerKA, ThambisettyM, WingoTS, PosnerSF, LingSM (2017) Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011-2013. Alzheimers Dement13, 28–37.
5.
AkushevichI, YashkinAP, KravchenkoJ, UkraintsevaS, StallardE, YashinAI (2018) Time trends in the prevalence of neurocognitive disorders and cognitive impairment in the United States: The effects of disease severity and improved ascertainment. J Alzheimers Dis64, 137.
6.
CallahanCM, ArlingG, TuW, RosenmanMB, CounsellSR, StumpTE, HendrieHC (2012) Transitions in care for older adults with and without dementia. J Am Geriatr Soc60, 813–820.
7.
DefinaLF, BarlowCE, RadfordNB, LeonardD, WillisBL (2016) The association between midlife cardiorespiratory fitness and later life chronic kidney disease: The Cooper Center Longitudinal Study. Prev Med89, 178–183.
8.
BartholdD, JoyceG, WhartonW, KehoeP, ZissimopoulosJ (2018) The association of multiple anti-hypertensive medication classes with Alzheimer’s disease incidence across sex, race, and ethnicity. PloS One13, e0206705.
9.
ZissimopoulosJM, BartholdD, BrintonRD, JoyceG (2017) Sex and race differences in the association between statin use and the incidence of Alzheimer disease. JAMA Neurol74, 225–232.
10.
HuntLJ, CovinskyKE, YaffeK, StephensCE, MiaoY, BoscardinWJ, SmithAK (2015) Pain in community-dwelling older adults with dementia: Results from the National Health and Aging Trends Study. J Am Geriatr Soc63, 1503–1511.
11.
KociolDR, HortonRJ, FonarowCG, ReyesME, ShawKL, O’ConnorMC, FelkerMG, HernandezFA (2011) Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: Data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) linked to Medicare claims. Circ Heart Fail4, 628–636.
12.
St. PeterWL, LiuJ, WeinhandlE, FanQ (2008) A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: A secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis51, 445–454.
13.
LeeE, GatzM, TsengC, SchneiderL, PawluczykS, WuA, DeapenD (2019) Evaluation of Medicare claims data as a tool to identify dementia. J Alzheimers Dis67, 769–778.
14.
ImfeldP, Brauchli PernusYB, JickSS, MeierCR (2013) Epidemiology, co-morbidities, and medication use of patients with Alzheimer’s disease or vascular dementia in the UK. J Alzheimers Dis35, 565.
